GUANHAO BIOTECH CO.,LTD. Guanhao Biotech Co.,Ltd. Stock
Equities
300238
CNE100001575
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.86 CNY | -0.37% |
|
-22.32% | -19.91% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 377M 52.23M | Sales 2023 | 404M 55.96M | Capitalization | 3.6B 498M |
|---|---|---|---|---|---|
| Net income 2022 | -308M -42.64M | Net income 2023 | 31M 4.29M | EV / Sales 2022 | 7.1 x |
| Net cash position 2022 | 47.22M 6.54M | Net cash position 2023 | 50.47M 6.99M | EV / Sales 2023 | 8.77 x |
| P/E ratio 2022 |
-8.86
x | P/E ratio 2023 |
113
x | Employees | 535 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 67.42% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.37% | ||
| 1 week | -22.32% | ||
| Current month | +6.26% | ||
| 1 month | +26.57% | ||
| 3 months | +24.40% | ||
| 6 months | -25.05% | ||
| Current year | -19.91% |
1 week
10.68
12.07
1 month
8.7815.15
Current year
7.4815.15
1 year
7.4823.38
3 years
7.4824.50
5 years
7.4840.50
10 years
7.4863.10
| Managers | Title | Age | Since |
|---|---|---|---|
Xin Zhi Wang
CEO | Chief Executive Officer | 61 | 20-06-29 |
Wei Kun Zhang
DFI | Director of Finance/CFO | 38 | 21-04-08 |
Shuang Bing Xian
BRD | Director/Board Member | 38 | 16-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yong Ming Zhang
CHM | Chairman | 52 | 18-04-26 |
Chao Deng
BRD | Director/Board Member | 58 | 23-06-20 |
Jun Hui Zhao
BRD | Director/Board Member | 48 | 06-08-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 10.86 | -0.37% | 13,579,410 |
| 24-05-16 | 10.9 | -0.64% | 13,968,600 |
| 24-05-15 | 10.97 | -2.66% | 14,503,600 |
| 24-05-14 | 11.27 | -0.79% | 23,227,600 |
| 24-05-13 | 11.36 | -7.27% | 30,729,840 |
End-of-day quote Shenzhen S.E., May 16, 2024
More quotes
Guanhao Biotech Co Ltd is a China-based company principally engaged in the research, development, production and distribution of regeneration medical materials and medical implanted devices. The Company primarily provides biological dura mater patches, chest general surgery department patching membranes (type P) and (type B), asepsis biological wound-surface protection membranes, type B dura matrix, intraocular lens as well as agent products. The Company is also engaged in provision of related technological services. The Company also provides related biotechnology services. The Company mainly conducts its business in the domestic market.
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -19.91% | 400M | |
| -5.43% | 182B | |
| +4.30% | 114B | |
| -3.09% | 68.38B | |
| +5.86% | 52.46B | |
| +8.15% | 44.25B | |
| +7.52% | 43.55B | |
| +25.54% | 32.69B | |
| +17.85% | 26.73B | |
| +1.00% | 25.79B |
- Stock Market
- Equities
- 300238 Stock
